Tagged with generic

USA The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient access to more affordable medicines.   In this election year I hope that the candidates will lay out their solutions…

Hungary MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges of smaller companies, its marketing strategy of its niche products, and its internationalization strategy.   Can you introduce yourself and…

USA The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs.   The question,…

Czech Republic Josef Kredba, country manager Czech Republic at G.L. Pharma, an Austrian pharmaceutical company, explains how the company has returned to growth in the challenging Czech generics market and shares his thoughts on market access and pricing conditions for both innovative and generic products.   On the one hand, authorities recognize…

Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…

Hungary Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies in Hungary, the generic manufacturer now stands as a fully owned subsidiary of the French Servier Group. However, even today…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

Czech Republic Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country. He delves into the growth of their biosimilars business — its portfolio share increased from eight to 15 percent in…

Hungary Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only…

Generics Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions strengthening its position.   Zentiva, a Czech Republic-based generics manufacturer, is on a mission to expand its reach after being…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Switzerland Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company.   As one of the first companies in the developing world to branch out into this segment – launching four biosimilar products between 2001 and 2011 –…